Trials / Completed
CompletedNCT00480662
A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)
A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alendronate | Duration of Treatment : 6 Months |
Timeline
- Start date
- 2001-10-01
- Primary completion
- 2002-10-01
- Completion
- 2002-10-01
- First posted
- 2007-05-31
- Last updated
- 2024-08-14
Source: ClinicalTrials.gov record NCT00480662. Inclusion in this directory is not an endorsement.